EMA Authorised: Grasustek (pegfilgrastim) — Juta Pharma GmbH

View source ↗

Summary

EMA authorised Grasustek (pegfilgrastim) for marketing by Juta Pharma GmbH; decision date 24 March 2026.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Neutropenia

Drugs mentioned

• Grasustek (pegfilgrastim)

Snippet

Status: Authorised. MAH: Juta Pharma GmbH. Decision date: 24/03/2026